Ginkgo Bioworks (DNA) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DNA, but not buy additional shares or sell existing shares.
View DNA analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 12-month price targets for Ginkgo Bioworks' shares. Their DNA share price forecasts range from $1.25 to $6.00. On average, they predict the company's share price to reach $4.10 in the next year. This suggests a possible upside of 141.2% from the stock's current price.
View analysts price targets for DNA or view top-rated stocks among Wall Street analysts.

Ginkgo Bioworks' stock was trading at $1.69 at the start of the year. Since then, DNA shares have increased by 0.6% and is now trading at $1.70.
View the best growth stocks for 2023 here.

Ginkgo Bioworks saw a increase in short interest in May. As of May 15th, there was short interest totaling 202,240,000 shares, an increase of 7.5% from the April 30th total of 188,130,000 shares. Based on an average trading volume of 20,070,000 shares, the days-to-cover ratio is currently 10.1 days. Approximately 16.2% of the company's stock are sold short.
View Ginkgo Bioworks' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our DNA earnings forecast.

ETFs with the largest weight of Ginkgo Bioworks (NYSE:DNA) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Innovation ETF (ARKK), Direxion Moonshot Innovators ETF (MOON), IQ U.S. Mid Cap R&D Leaders ETF (MRND), Putnam BioRevolution ETF (SYNB), VegTech Plant-based Innovation & Climate ETF (EATV) and Hartford Schroders ESG US Equity ETF (HEET).

Ginkgo Bioworks issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $275.00M-, compared to the consensus revenue estimate of $304.06 million.

Ginkgo Bioworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "DNA."

Ginkgo Bioworks' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (11.72%), ARK Investment Management LLC (7.95%), BlackRock Inc. (2.44%), Sumitomo Mitsui Trust Holdings Inc. (2.06%), Nikko Asset Management Americas Inc. (2.06%) and State Street Corp (0.71%). Insiders that own company stock include Barry Canton, Christian O Henry, Jason R Kelly, Marie E Fallon, Marijn E Dekkers, Mark E Dmytruk, Reshma P Shetty and Shyam Sankar.
View institutional ownership trends.

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DNA stock can currently be purchased for approximately $1.70.

Ginkgo Bioworks (NYSE:DNA) has a market capitalization of $3.55 billion and generates $477.71 million in revenue each year. The company earns $-2,104,930,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis.

The company employs 1,292 workers across the globe.

Ginkgo Bioworks' mailing address is 955 Fifth Avenue, New York NY, 10075. The official website for the company is www.eagleequityptnrs.com. The company can be reached via phone at 877-442-5362 or via email at investors@ginkgobioworks.com.